Double‐hit lymphoma: So what?-Reference-Cited by-同舟云学术

Double‐hit lymphoma: So what?

Published:2019-06 Issue:S1 Volume:37 Page:19-23
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Davies Andrew¹

Affiliation:

1. Cancer Research UK Centre, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, Somers Cancer Research BuildingSouthampton General Hospital Southampton UK

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2581

Reference28 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

2. Prognostic significance of MYC single, double, triple hit and MYC translocation partner status in diffuse large B‐cell lymphoma—a study by the Lunenburg lymphoma biomarker consortium (LLBC);Rosenwald A;Blood,2018

3. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

4. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

5. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib;British Journal of Haematology;2023-11-27

2. High-grade B-cell lymphoma with MYC and BCL2 rearrangements presenting as a cervical mass;Pathology;2023-10

3. Double-Expressor Lymphoma in a Young Child—A Case Report and Review of Literature;Indian Journal of Medical and Paediatric Oncology;2023-09-22

4. Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma;EMBO Molecular Medicine;2023-05-09

5. Strategies for Targeting MYC;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15